Treatment of ST-elevation myocardial infarction - an observational study
Insights
Primary PCI and thrombolytic therapy show similar outcomes for ST-elevation myocardial infarction patients. Many patients experienced treatment delays, highlighting the need for timely reperfusion strategies.
Area of Science:
- Cardiology
- Emergency Medicine
- Public Health
Background:
- ST-elevation myocardial infarction (STEMI) requires timely reperfusion therapy, with primary percutaneous coronary intervention (PCI) and thrombolytic therapy as key options.
- Geographical factors in regions like Norway necessitate consideration of thrombolytic therapy due to transport times to PCI centers.
- Minimizing delays in reperfusion treatment is crucial regardless of the chosen therapy.
Purpose of the Study:
- To compare the outcomes of primary PCI versus thrombolytic therapy for STEMI in Central Norway.
- To assess whether reperfusion therapy was administered within recommended timeframes.
Main Methods:
- A comparative study using registry data and patient medical records from 2015-16.
- Analysis of 648 STEMI patients treated with either primary PCI or thrombolytic therapy.
- Outcomes assessed included 30-day mortality, ejection fraction, bleeding complications, and time-to-treatment.
Main Results:
- No statistically significant difference in 30-day mortality between primary PCI (5.5%) and thrombolysis (5.6%).
- Similar ejection fraction and no significant bleeding complications observed in both groups.
- 45% of patients received reperfusion therapy later than guideline-recommended times.
Conclusions:
- Primary PCI and thrombolytic therapy offer comparable outcomes for unselected STEMI patients.
- Significant delays in initiating reperfusion therapy were noted, emphasizing the need for process improvements.
- Thrombolytic therapy is a viable option when PCI center access may exceed guideline time limits.
Background:
ST-elevation myocardial infarction is treated with reperfusion, either in the form of primary percutaneous coronary intervention (PCI) or thrombolytic therapy. The choice of treatment depends on transport time to the nearest PCI centre. Norway's geography means that thrombolytic therapy will be appropriate for many patients. Irrespective of treatment choice, it is important to avoid delays. We wished to compare the outcomes of primary PCI and thrombolytic therapy in our healthcare region and to examine whether reperfusion therapy was administered within the recommended time window.
Material And Method:
Using registry data and patient medical records, we compared the outcomes of primary PCI and thrombolytic therapy in cases of ST-elevation myocardial infarction in the Central Norway Regional Health Authority in the period 2015-16. The outcomes analysed were 30-day mortality, ejection fraction measured by echocardiography during the hospital stay, incidence of bleeding complications, and time from diagnosis to start of treatment.
Results:
The study population comprised 648 patients with ST-elevation myocardial infarction. Of these, 382 were treated with primary PCI and 266 received thrombolytic therapy. The 30-day mortality was 5.5 % in the primary PCI group and 5.6 % in the thrombolysis group (p = 1.0). There were no significant differences in ejection fraction and no cases of serious bleeding. In 45 % of the total population, reperfusion therapy was started later than recommended in guidelines.
Interpretation:
There was no statistically significant difference in mortality or ejection fraction when comparing primary PCI and thrombolytic therapy in an unselected population with ST-elevation myocardial infarction. Many patients experienced delayed start of treatment . It is important to take action to reduce delays at all stages of the therapeutic chain. Thrombolytic therapy should be considered when it is unclear whether transport time to a PCI centre will exceed that recommended in guidelines.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:14Myocarditis III: Medical Management
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:20Angina V: Nursing Management